FilippoMontemu1 Profile Banner
Filippo Montemurro Profile
Filippo Montemurro

@FilippoMontemu1

Followers
2K
Following
2K
Media
51
Statuses
2K

Senior Medical Director, F. Hoffmann La Roche

Basel, Switzerland
Joined November 2018
Don't wanna be here? Send us removal request.
@FilippoMontemu1
Filippo Montemurro
3 days
A Life on the Line and $250K in Medical Debt Amid Insurer Denials The battle of bots…always saddened by this type stories☹️😔.
0
0
1
@FilippoMontemu1
Filippo Montemurro
6 days
This is interesting. By binding to NK1R, the P protein can affect several aspects of cancer hallmarks. This intriguing article suggests an anticaner role for NK1R inhibitors commonly used to treat severe nausea an vomiting due to chemotherapy.
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm...
0
3
8
@FilippoMontemu1
Filippo Montemurro
6 days
Microenvironmental differences may account for the different outcomes of breast cancer in black vs white Americans? Need to give this a "slow reading". Most important, are these druggable?
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Racial disparities in the clinical outcomes of triple-negative breast cancer (TNBC) have been well-documented, but the underlying biological mechanisms remain poorly understood. To investigate these...
1
0
2
@FilippoMontemu1
Filippo Montemurro
8 days
en.wikipedia.org
0
0
0
@FilippoMontemu1
Filippo Montemurro
8 days
In the clinic, only 4.3% of patients with a positive test will have breast cancer at 90% SN and SP, and if those could be pushed to 99%, the figure would be 33%. This is because the baseline prevalence of the condition that the test targets is part of the PPV equation.
1
0
0
@FilippoMontemu1
Filippo Montemurro
8 days
The graph I have generate depicts two tests differing in SN and SP (90 and 99) and three situations, the first representing the real prevalence of breast cancer in the population that is the subject of the screening 0.5%). While in experimental conditions a test can perform super.
1
0
0
@FilippoMontemu1
Filippo Montemurro
8 days
Tweet media one
1
0
0
@FilippoMontemu1
Filippo Montemurro
8 days
New Mammography Tools — The Need for Clinically Meaningful Assessment Standards | A must-read editorial in NEJM. A memento that prevalences that are used in samples to develop new tests may be far from the real prevalence in the clinic.
Tweet card summary image
nejm.org
AI mammography aids are being sold as additions to mammography screening, with direct-to-consumer marketing touting improved cancer-detection rates, despite a lack of evidence of clinical effective...
1
0
0
@FilippoMontemu1
Filippo Montemurro
11 days
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial | Journal of Clinical Oncology Another valuable info from the POSITIVE trial.
Tweet card summary image
ascopubs.org
PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth in the POSITIVE...
0
0
1
@FilippoMontemu1
Filippo Montemurro
11 days
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast. The old issue of AIs being detrimental for cardiovascular health is rediscussed in this nice paper. AIs seem to reduce cardiovascular morbidity and mortality.
Tweet card summary image
academic.oup.com
AbstractBackground. There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined r
0
1
3
@FilippoMontemu1
Filippo Montemurro
16 days
RT @drsarahsam: Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast can….
Tweet card summary image
pmc.ncbi.nlm.nih.gov
Cancer remains a major global health challenge, and growing evidence suggests that physical activity is a key modifiable factor that may improve survival outcomes in cancer patients. However, a...
0
26
0
@FilippoMontemu1
Filippo Montemurro
16 days
In my opinion, this is the best reading of the year so far (at least for me). Worthy of a "Slow reading". KUDOS to the authors.
Tweet card summary image
nature.com
Nature Medicine - Multi-omic single-cell and spatial analyses of lung cancer brain metastases from multiple cohorts identify high levels of chromosomal instability and a neural-like profile in...
0
0
3
@FilippoMontemu1
Filippo Montemurro
17 days
RT @LoiSher: 🏃‍♀️🏋️🏋️‍♂️🎾👟Further evidence on the benefit of physical activity #exercise #strength training for chronic medical conditions….
0
3
0
@FilippoMontemu1
Filippo Montemurro
20 days
Conoccurring mutations in GATA3 mut tumors may reveal actionable targets in HR+ resistant tumors. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes - PubMed
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
The distinct landscape in GATA3mut MBC ctDNA highlights critical information when assessing candidacy for targeted therapies. To our knowledge, this is the first ctDNA-based GATA3mut landscape...
1
5
10
@FilippoMontemu1
Filippo Montemurro
20 days
A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer - PubMed A nice paper on a clinical dilemma
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Survival was higher for patients with CAM compared with MBC and was similar to patients with LABC. Though the LABC group demonstrated better recurrence-free survival than the CAM group, these numbers...
0
1
2
@FilippoMontemu1
Filippo Montemurro
27 days
This looks promising. for sure, worthy of a "slow reading".
@ASCOPost
The ASCO Post
29 days
DESTINY-Breast09: First-line T-DXd + pertuzumab significantly prolongs PFS vs THP in HER2+ mBC:.40.7 vs 26.9 mo (HR 0.56; P<.00001)‼️.New first-line standard?.Led by @stolaney1 and discussed by @claudine_isaacs at #ASCO25 #BreastCancer .➡️
Tweet media one
0
0
1
@FilippoMontemu1
Filippo Montemurro
27 days
Interesting analysis from I-SPY investigators. Although nonsignificant, the negative prognostic impact of cT 3/4 at diagnosis in HER2-positive patients achieving pCR is consistent with other studies.
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
I-SPY 2 TRIAL beginning December 31, 2009: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2), NCT01042379.
0
4
10
@FilippoMontemu1
Filippo Montemurro
1 month
RT @NEJMEvidence: Review Article: “Reading and Interpreting Quality-of-Life Results in Cancer Trials” by @MassimoDiMaio75: .
0
19
0